Calcitonin salmon: structure, approved uses, key trials and status

Calcitonin salmon is a synthetic peptide hormone first approved in the United States in 1975. This guide covers its structure, label, key human trials and status as of November 17, 2026.

Complete guide6 min read

Key takeaway

Calcitonin salmon is a 32-amino-acid peptide that activates calcitonin receptors. The Miacalcin label gives 1975 as its initial U.S. approval year. In a label meta-analysis of 21 trials, malignancies were reported in 4.1% of treated patients versus 2.9% on placebo. Since 2014, labels have limited its osteoporosis use to patients for whom other treatments are not suitable.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“According to the Miacalcin label, calcitonin salmon was first approved in the United States in 1975.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited2 in this article · 2 across 1 article on Calcitonin salmon
Related productsIncretin analogs

Calcitonin salmon is a synthetic copy of the calcitonin hormone found in salmon. It is approved in the United States for Paget’s disease of bone, hypercalcemia and postmenopausal osteoporosis, with limits on its use. This guide covers its structure, label, key trials and status, using sources checked on November 17, 2026.

Quick answer: Calcitonin salmon is a prescription peptide drug that slows bone breakdown. The Miacalcin label approves it for symptomatic Paget’s disease of bone and postmenopausal osteoporosis when alternatives are not suitable, and for hypercalcemia. Labels say the need for continued therapy should be re-evaluated periodically, because of a possible link with malignancy.

Vitrapep does not sell calcitonin salmon; this page is a reference summary of published research and regulatory information. It is not medical advice.

What is calcitonin salmon?

Calcitonin salmon is a synthetic peptide of 32 amino acids. The Miacalcin label says its sequence is the same as calcitonin of salmon origin (Miacalcin label, 2024). PubChem, citing ChEBI, describes a cyclic peptide closed by a disulfide bridge between the cysteines at positions 1 and 7. PubChem lists the formula C145H240N44O48S2 and a molecular weight of 3431.9 g/mol (PubChem CID 16220016).

According to the Miacalcin label, calcitonin salmon was first approved in the United States in 1975. Drugs@FDA’s earliest dated record is for Calcimar, approved April 17, 1978, and now discontinued (Drugs@FDA, NDA 017769). A second Calcimar record shows no approval date. Miacalcin was approved on July 3, 1986, and is still marketed (Drugs@FDA, NDA 017808). For related hormones, see our overview of peptide hormones.

Table 1

Calcitonin salmon: key facts

Fact Detail
Structure 32 amino acids; a disulfide bridge joins positions 1 and 7 into a ring
Class Calcitonin receptor agonist
Molecular formula C145H240N44O48S2 (PubChem)
Molecular weight 3431.9 g/mol (PubChem)
First FDA approval 1975, per the Miacalcin label; earliest dated Drugs@FDA record April 17, 1978 (Calcimar)
Approved brands Miacalcin (marketed); Calcimar and Fortical (discontinued); generic products

How does calcitonin salmon work?

The label calls it “a calcitonin receptor agonist.” It acts mainly on bone, with direct effects on the kidney and the gut as well. Calcitonin receptors have been found on osteoclasts, the cells that resorb bone, and on osteoblasts.

The label describes a marked, short-lived drop in bone resorption, and a smaller lasting drop with prolonged use. It links this to fewer osteoclasts and lower osteoclast activity. In the kidney, calcitonin salmon raises the excretion of phosphate, calcium and sodium. Serum calcium falls, more so in children and in people with faster bone turnover.

The label says salmon calcitonin acts much like mammalian calcitonins, but it is more potent by weight and acts longer. It also notes that calcitonin’s role in normal human bone physiology is “still not completely elucidated.”

What is calcitonin salmon approved for?

Section 1 of the current Miacalcin label lists three indications and one limitation:

  • Paget’s disease of bone: “Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable.”
  • Hypercalcemia: “Treatment of hypercalcemia,” including early treatment of hypercalcemic emergencies along with other appropriate agents.
  • Postmenopausal osteoporosis: treatment when alternative treatments are not suitable, in women more than 5 years past menopause. The label adds: “Fracture reduction efficacy has not been demonstrated.”
  • Limitation of use: because of “the possible association between malignancy and calcitonin salmon use,” the need for continued therapy should be re-evaluated periodically.

Other calcitonin salmon products carry a narrower label. One generic label lists only postmenopausal osteoporosis, reserved for patients for whom alternatives are not suitable (DailyMed, ANDA 076396). It states the product “has not been shown to increase spinal bone mineral density in early postmenopausal women.”

What did the key trials of calcitonin salmon show?

PROOF (vertebral fractures). This five-year, double-blind, placebo-controlled trial enrolled 1,255 postmenopausal women with established osteoporosis. All also received calcium and vitamin D. It compared three levels of calcitonin salmon with placebo. The trial predates ClinicalTrials.gov registration.

The middle level reduced the risk of new vertebral fractures by 33% (relative risk 0.67; 95% CI 0.47 to 0.97; P=0.03). The lowest and highest levels did not differ significantly from placebo. Lumbar spine bone density rose 1% to 1.5% in all active groups. Of the 1,255 women, 511 completed five years (Chesnut et al., 2000).

Knee osteoarthritis (not an approved use). Two Phase 3 trials tested an investigational calcitonin salmon formulation in 2,206 people with symptomatic knee osteoarthritis (NCT00486434, NCT00704847). Neither showed a significant effect on joint space narrowing over 24 months. The authors concluded it “did not provide reproducible clinical benefits” (Karsdal et al., 2015). ClinicalTrials.gov lists the second trial as terminated. It states: “Male subjects were terminated due to an imbalance in prostate cancer events.”

What side effects does the calcitonin salmon label list?

The Miacalcin label has no boxed warning. Its warnings cover serious hypersensitivity reactions, low blood calcium, malignancy, antibody formation and urine sediment abnormalities.

Its most common adverse reactions are nausea with or without vomiting (10%) and local site inflammation (10%). Flushing of the face or hands is listed at 2% to 5%. The generic osteoporosis-only label lists local symptoms at the site of use, back pain (5%), joint pain (4%) and headache (3%).

The malignancy warning rests on a meta-analysis of 21 randomized, controlled trials with 10,883 patients. Malignancies were reported in 254 of 6,151 treated patients (4.1%) and 137 of 4,732 placebo patients (2.9%). The 2014 label says a single large 5-year trial heavily influenced the result. It adds that “a definitive causal relationship” cannot be established from this meta-analysis (Miacalcin label, 2014).

What is the regulatory status of calcitonin salmon, and is it used in research?

Calcitonin salmon is a prescription drug. Drugs@FDA lists Miacalcin with a “Prescription” status. A second Miacalcin application, approved in 1995, is listed as discontinued (Drugs@FDA, NDA 020313). So is Fortical, approved in 2005 (Drugs@FDA, NDA 021406). DailyMed lists several generic labels.

A key label change came in March 2014. That label revision added the limitation of use and the malignancy warning, both marked as recent major changes dated 03/2014. FDA’s Drug Safety Communications page, covering January 2020 to November 9, 2026, lists none about calcitonin (FDA, 2026). WADA’s 2026 Prohibited List does not name calcitonin.

Human trials outside the label continue, including the nerve pain study below.

Frequently asked questions about calcitonin salmon

Is calcitonin salmon a peptide?

Yes. The label describes it as a synthetic polypeptide of 32 amino acids. See types of peptides for how peptides are grouped.

Why is it called salmon calcitonin?

Its amino acid sequence matches calcitonin of salmon origin. The drug itself is made synthetically or, for Fortical, recombinantly.

Does calcitonin salmon cause cancer?

The label reports a higher malignancy rate in a meta-analysis (4.1% versus 2.9%). It says this suggests an increased risk, but a definitive causal relationship cannot be established from that analysis.

Is calcitonin salmon still available?

Yes, by prescription. Miacalcin is listed as marketed, and DailyMed lists generic labels. Calcimar and Fortical are discontinued.

Is calcitonin banned in sport?

WADA’s 2026 Prohibited List does not name it. Athletes should check with their anti-doping organization.

What to know now

  • What it is: a 32-amino-acid calcitonin receptor agonist, 3431.9 g/mol.
  • First approval: 1975, per the Miacalcin label.
  • Approved for: Paget’s disease and osteoporosis when alternatives are not suitable, and hypercalcemia.
  • Key evidence: PROOF (1,255 women) showed fewer vertebral fractures at one of three levels only.
  • Safety: no boxed warning; a malignancy warning since March 2014.
  • Status: prescription only; not named on the WADA 2026 list.

What we’re watching

A Phase 3 trial at Tanta University testing salmon calcitonin against saline to prevent nerve pain after shingles (NCT07655804). It plans 168 patients, with primary completion estimated for April 1, 2027. We also watch DailyMed for label revisions, including any change to the malignancy warning. See our teriparatide and abaloparatide guides for other bone peptides.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Mylan Institutional 2024, Miacalcin (calcitonin salmon): Prescribing information; Novartis Pharmaceuticals 2014, Miacalcin (calcitonin-salmon): Prescribing information; National Center for Biotechnology Information. PubChem compound summary for CID 16220016, PubChem compound summary for CID 16220016, Calcitonin salmon; U.S. Food and Drug Administration. Drugs@FDA: Calcimar, Drugs@FDA: Calcimar, NDA 017769; U.S. Food and Drug Administration. Drugs@FDA: Miacalcin, Drugs@FDA: Miacalcin, NDA 017808; U.S. Food and Drug Administration. Drugs@FDA: Fortical, Drugs@FDA: Fortical, NDA 021406; U.S. Food and Drug Administration. Drugs@FDA: Miacalcin, Drugs@FDA: Miacalcin, NDA 020313; Apotex Corp 2023, Calcitonin salmon (synthetic origin): Prescribing information; Chesnut 2000, American Journal of Medicine, 109; Karsdal 2015, Osteoarthritis and Cartilage, 23; Nordic Bioscience A/S. ClinicalTrials.gov record NCT00704847: Phase 3 trial in knee osteoarthritis (OA 2 study) . Retrieved November 17, ClinicalTrials.gov record NCT00704847: Phase 3 trial in knee osteoarthritis (OA 2 study); U.S. Food and Drug Administration 2026, Drug safety communications; Tanta University. ClinicalTrials.gov record NCT07655804: Phase 3 trial in acute herpes zoster . Retrieved November 17, ClinicalTrials.gov record NCT07655804: Phase 3 trial in acute herpes zoster; World Anti-Doping Agency 2025, World Anti-Doping Code International Standard: Prohibited List 2026. All 14 citations

Back to the research library

References

  1. Mylan Institutional. (2024). Miacalcin (calcitonin salmon): Prescribing information (revised September 2024). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26caf31f-7f7c-48a8-a1ac-35d2ceefda2b
  2. Novartis Pharmaceuticals. (2014). Miacalcin (calcitonin-salmon): Prescribing information (revised March 2014). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/017808s035lbl.pdf
  3. National Center for Biotechnology Information. PubChem compound summary for CID 16220016, Calcitonin salmon. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/16220016
  4. U.S. Food and Drug Administration. Drugs@FDA: Calcimar, NDA 017769. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017769
  5. U.S. Food and Drug Administration. Drugs@FDA: Miacalcin, NDA 017808. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017808
  6. U.S. Food and Drug Administration. Drugs@FDA: Fortical, NDA 021406. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021406
  7. U.S. Food and Drug Administration. Drugs@FDA: Miacalcin, NDA 020313. Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020313
  8. Apotex Corp. (2023). Calcitonin salmon (synthetic origin): Prescribing information (ANDA 076396; revised December 2023). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c82eb602-12e1-692b-d660-f8d5b5736b54
  9. Chesnut, C. H., 3rd, Silverman, S., Andriano, K., et al. (2000). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. American Journal of Medicine, 109(4), 267–276. https://doi.org/10.1016/s0002-9343(00)00490-3
  10. Karsdal, M. A., Byrjalsen, I., Alexandersen, P., et al. (2015). Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: Results from two phase 3 trials. Osteoarthritis and Cartilage, 23(4), 532–543. https://doi.org/10.1016/j.joca.2014.12.019
  11. Nordic Bioscience A/S. ClinicalTrials.gov record NCT00704847: Phase 3 trial in knee osteoarthritis (OA 2 study). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00704847
  12. U.S. Food and Drug Administration. (2026). Drug safety communications (content current as of November 9, 2026). https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications
  13. Tanta University. ClinicalTrials.gov record NCT07655804: Phase 3 trial in acute herpes zoster. Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT07655804
  14. World Anti-Doping Agency. (2025). World Anti-Doping Code International Standard: Prohibited List 2026 (in effect January 1, 2026). https://www.wada-ama.org/en/prohibited-list